Key result
Cardiomyocyte-specific overexpression of RGS2eb inhibited cardiac hypertrophy and improved cardiac function in mice following 4 weeks of transverse aortic constriction compared to wild-type controls.
Why the study?
Does cardiomyocyte specific overexpression of RGS2eb inhibit cardiac hypertrophy and improve function in mice subjected to pressure overload?
Does cardiomyocyte specific overexpression of RGS2eb inhibit cardiac hypertrophy and improve function in mice subjected to pressure overload?
Cardiomyocyte-specific overexpression of the RGS2eb domain limits pathological cardiac hypertrophy and improves cardiac function in a mouse model of pressure overload.
Answers are grounded in this paper and cite their sources.
Preclinical finding only; leaves open whether RGS2eb modulation can treat human pressure-overload cardiomyopathy.
Regulator of G protein signalling 2 (RGS2) is known to play a protective role in maladaptive cardiac hypertrophy and heart failure via its ability to inhibit G q - and G s - mediated GPCR signalling. We previously demonstrated that RGS2 can also inhibit protein translation and can thereby attenuate cell growth. This G protein-independent inhibitory effect has been mapped to a 37 amino acid domain (RGS2 eb ) within RGS2 that binds to eukaryotic initiation factor 2B (eIF2B). When expressed in neonatal rat cardiomyocytes, RGS2 eb attenuates both protein synthesis and hypertrophy induced by G q - and G s - activating agents. In the current study, we investigated the potential cardioprotective role of RGS2 eb by determining whether RGS2 eb transgenic (RGS2 eb TG) mice with cardiomyocyte specific overexpression of RGS2 eb show resistance to the development of hypertrophy in comparison to wild-type (WT) controls. Using transverse aortic constriction (TAC) in a pressure-overload hypertrophy model, we demonstrated that cardiac hypertrophy was inhibited in RGS2 eb TG mice compared to WT controls following four weeks of TAC. Expression of the hypertrophic markers atrial natriuretic peptide (ANP) and β-myosin heavy chain (MHC-β) was also reduced in RGS2 eb TG compared to WT TAC animals. Furthermore, cardiac function in RGS2 eb TG TAC mice was significantly improved compared to WT TAC mice. Notably, cardiomyocyte cell size was significantly decreased in TG compared to WT TAC mice. These results suggest that RGS2 may limit pathological cardiac hypertrophy at least in part via the function of its eIF2B-binding domain.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) studied Cardiac hypertrophy. Cardiomyocyte specific overexpression of RGS2eb vs. Wild-type (WT) controls was evaluated on Cardiac hypertrophy and cardiac function following transverse aortic constriction (TAC). Cardiomyocyte-specific overexpression of RGS2eb inhibited cardiac hypertrophy and improved cardiac function in mice following 4 weeks of transverse aortic constriction compared to wild-type controls.
Synapse has enriched 10 related papers. Consider them for comparative context: